Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

Covington Represents Israeli Biotechnology Company NeuroSense Therapeutics in Nasdaq IPO

Press Release December 13, 2021

  • News and Insights
  • Covington Represents Israeli Biotechnology Company NeuroSense Therapeutics in Nasdaq IPO

Covington Represents Israeli Biotechnology Company NeuroSense Therapeutics in Nasdaq IPO

December 13, 2021

NEW YORK— Covington advised NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases such as ALS, Alzheimer’s and Parkinson’s disease, on its U.S. initial public offering and listing on Nasdaq under the symbol NRSN.

The Covington team included Brian Rosenzweig, Sarah Griffiths, Jae Kim, and Tyler Cochrane (capital markets), Ansgar Simon and Jon Endean (tax), Peter Safir (regulatory), and Gregory Discher and Melody Wu (intellectual property).

Related Professionals

Share links:

Share links:

Related Practices

Related Offices

Related Regions

Related News & Insights